Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $6.2500 (-1.26%) ($6.1900 - $6.5300) on Mon. Sep. 16, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.69% (three month average) | RSI | 55 | Latest Price | $6.2500(-1.26%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 2.2% a day on average for past five trading days. | Weekly Trend | ADMS advances 0.4% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IGOV(11%) LQD(6%) VCIT(6%) SHY(5%) JETS(4%) | Factors Impacting ADMS price | ADMS will decline at least -1.345% in a week (0% probabilities). INDA(-10%) URA(-9%) XLE(-8%) USO(-8%) XLV(-7%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.345% (StdDev 2.69%) | Hourly BBV | 0 () | Intraday Trend | -1.3% | | | |
|
5 Day Moving Average | $6.12(2.12%) | 10 Day Moving Average | $6(4.17%) | 20 Day Moving Average | $6.06(3.14%) | To recent high | -2.6% | To recent low | 21.1% | Market Cap | $177m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |